AbbVie Stock Price Target and Analyst Ratings (NYSE:ABBV)

Analyst Price Target for ABBV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$115.75

▲ +5.18% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $115.75, with a high forecast of $144.00 and a low forecast of $95.00. The average price target represents a 5.18% upside from the last price of $110.05.

Buy

The current consensus among 16 polled investment analysts is to buy stock in AbbVie. This rating has held steady since May 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
2 hold ratings
2 sell ratings

Ratings as of

10/30/2019

0 strong buy ratings
9 buy ratings
2 hold ratings
2 sell ratings

Ratings as of

1/28/2020

0 strong buy ratings
10 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

4/27/2020

0 strong buy ratings
14 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/26/2020

0 strong buy ratings
14 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

10/24/2020

0 strong buy ratings
16 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

1/22/2021

0 strong buy ratings
14 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
13 buy ratings
2 hold ratings
1 sell ratings

Ratings as of

4/22/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/7/2021	Royal Bank of Canada	Initiated Coverage		$135.00	Low	i
3/30/2021	SVB Leerink	Boost Price Target	Outperform	$140.00 ➝ $144.00	Low	i
2/4/2021	SVB Leerink	Boost Price Target	In-Line ➝ Outperform	$128.00 ➝ $140.00	Low	i
2/4/2021	Royal Bank of Canada	Boost Price Target	Outperform	$129.00 ➝ $135.00	Low	i
2/4/2021	Mizuho	Boost Price Target	Buy	$117.00 ➝ $126.00	Low	i Rating by Vamil Divan at Mizuho
1/28/2021	Morgan Stanley	Lower Price Target	Overweight	$120.00 ➝ $116.00	Medium	i
12/16/2020	SVB Leerink	Boost Price Target	Outperform	$119.00 ➝ $128.00	Medium	i
12/15/2020	Mizuho	Boost Price Target		$111.00 ➝ $117.00	Medium	i Rating by Vamil Divan at Mizuho
11/30/2020	Morgan Stanley	Boost Price Target	Positive ➝ Overweight	$108.00 ➝ $120.00	Low	i
11/18/2020	BMO Capital Markets	Initiated Coverage	Outperform	$123.00 ➝ $123.00	Medium	i
11/10/2020	Sanford C. Bernstein	Initiated Coverage	Outperform	$120.00	High	i
11/2/2020	SVB Leerink	Lower Price Target	Outperform	$122.00 ➝ $119.00	High	i
10/23/2020	Truist	Initiated Coverage	Buy	$110.00	Low	i
10/20/2020	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell		High	i
10/16/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$115.00 ➝ $120.00	Low	i
9/29/2020	Berenberg Bank	Initiated Coverage	Hold	$98.00	Low	i
9/27/2020	Mizuho	Reiterated Rating	Buy	$111.00	Low	i Rating by Vamil Divan at Mizuho
9/2/2020	Citigroup	Boost Price Target	Buy	$98.00 ➝ $105.00	Medium	i
8/20/2020	Morgan Stanley	Boost Price Target	Overweight	$95.00 ➝ $108.00	Medium	i
8/3/2020	Mizuho	Boost Price Target	Buy	$110.00 ➝ $111.00	Low	i Rating by Vamil Divan at Mizuho
8/3/2020	Royal Bank of Canada	Boost Price Target	Outperform	$125.00 ➝ $127.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
6/29/2020	Mizuho	Boost Price Target	Top Pick ➝ Buy	$101.00 ➝ $110.00	Low	i Rating by Vamil Divan at Mizuho
6/25/2020	Royal Bank of Canada	Boost Price Target	Outperform	$102.00 ➝ $125.00	Medium	i Rating by Randall Stanicky at Royal Bank of Canada
6/23/2020	Atlantic Securities	Upgrade	Neutral ➝ Overweight	$115.00	Medium	i
6/18/2020	Royal Bank of Canada	Reiterated Rating	Buy	$102.00	Low	i
6/17/2020	UBS Group	Boost Price Target		$96.00 ➝ $109.00	Low	i
6/10/2020	Evercore ISI	Initiated Coverage	Buy	$111.00	High	i Rating by Joshua Schimmer at Evercore ISI
6/10/2020	Piper Sandler	Boost Price Target		$97.00 ➝ $110.00	High	i
6/9/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform		Low	i
6/2/2020	Argus	Upgrade	Hold ➝ Buy	$91.40 ➝ $115.00	Low	i
5/28/2020	Royal Bank of Canada	Reiterated Rating	Buy	$102.00	Low	i
5/18/2020	Bank of America	Initiated Coverage	Neutral	$95.00	Low	i
5/12/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$105.00	Medium	i
5/11/2020	Morgan Stanley	Reiterated Rating	Overweight	$95.00	High	i
5/11/2020	SVB Leerink	Boost Price Target	Outperform	$107.00 ➝ $122.00	High	i
5/4/2020	SVB Leerink	Boost Price Target	Outperform	$103.00 ➝ $107.00	Low	i
5/1/2020	Mizuho	Reiterated Rating	Buy	$100.00	Medium	i Rating by Vamil Divan at Mizuho
4/20/2020	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$79.00 ➝ $93.00	Low	i
4/13/2020	UBS Group	Lower Price Target	Buy	$106.00 ➝ $96.00	Low	i
4/12/2020	Royal Bank of Canada	Reiterated Rating	Hold	$79.00	Low	i
3/23/2020	Societe Generale	Downgrade	Buy ➝ Hold		High	i
2/27/2020	Barclays	Initiated Coverage	Equal Weight	$97.00 ➝ $97.00	High	i
2/18/2020	Cowen	Boost Price Target	Outperform	$98.00 ➝ $105.00	Low	i Rating by Steve Scala at Cowen Inc
2/10/2020	Mizuho	Boost Price Target		$96.00 ➝ $104.00	High	i Rating by Vamil Divan at Mizuho
2/7/2020	Piper Sandler	Boost Price Target	Overweight	$95.00 ➝ $97.00	Low	i
2/5/2020	Mizuho	Initiated Coverage	Buy	$96.00 ➝ $96.00	Low	i
1/23/2020	Royal Bank of Canada	Reiterated Rating	Hold	$86.00	High	i
1/6/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$86.00	Low	i
1/3/2020	Bank of America	Downgrade	Buy ➝ Neutral		Low	i
12/26/2019	Cowen	Boost Price Target	Outperform	$90.00 ➝ $98.00	Low	i Rating by Steve Scala at Cowen Inc
11/20/2019	Citigroup	Boost Price Target	Buy	$90.00 ➝ $98.00	Medium	i Rating by Andrew Baum at Citigroup Inc.
11/19/2019	UBS Group	Boost Price Target	Buy	$79.00 ➝ $96.00	High	i Rating by Navin Jacob at UBS Group AG
11/1/2019	Piper Jaffray Companies	Boost Price Target		$81.00 ➝ $90.00	High	i Rating by Christopher Raymond at Piper Jaffray Companies
9/26/2019	Citigroup	Upgrade	Neutral ➝ Buy	$87.00 ➝ $90.00	Medium	i Rating by Andrew Baum at Citigroup Inc.
9/24/2019	Cowen	Set Price Target	Buy	$90.00	Low	i Rating by Steve Scala at Cowen Inc
9/12/2019	UBS Group	Upgrade	Neutral ➝ Buy	$85.00 ➝ $79.00	Low	i
9/4/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$80.00 ➝ $81.00	Medium	i Rating by Christopher Raymond at Piper Jaffray Companies
8/20/2019	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$80.00	High	i Rating by Christopher Raymond at Piper Jaffray Companies
7/26/2019	Piper Jaffray Companies	Set Price Target	Hold	$80.00	N/A	i Rating by Christopher Raymond at Piper Jaffray Companies
7/2/2019	SVB Leerink	Upgrade	Buy		Low	i Rating by Geoff Porges at SVB Leerink LLC
6/27/2019	Wolfe Research	Upgrade	Underperform ➝ Peer Perform		Medium	i
6/26/2019	Citigroup	Reiterated Rating	Hold		Medium	i Rating by Andrew Baum at Citigroup Inc.
6/26/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$88.00	High	i Rating by G. Porges at SVB Leerink LLC
5/28/2019	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$84.00	High	i
4/28/2019	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$71.00 ➝ $79.00	Low	i
4/26/2019	Credit Suisse Group	Set Price Target	Sell	$78.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
3/25/2019	Argus	Downgrade	Buy ➝ Hold		Low	i
2/14/2019	Barclays	Reiterated Rating	Hold	$86.00	Low	i
1/25/2019	Credit Suisse Group	Set Price Target	Hold	$79.00	High	i Rating by Vamil Divan at Credit Suisse Group AG
1/23/2019	UBS Group	Reiterated Rating	Neutral ➝ Neutral	$97.00 ➝ $91.00	Low	i
1/17/2019	Credit Suisse Group	Upgrade	Hold	$79.00	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
1/3/2019	Bank of America	Downgrade	Buy ➝ Neutral		Medium	i Rating by Jason Gerberry at Bank of America Co.
12/26/2018	Standpoint Research	Initiated Coverage	Buy ➝ Buy		High	i
12/20/2018	Morgan Stanley	Set Price Target	Hold	$88.00	High	i Rating by David Risinger at Morgan Stanley
11/6/2018	Argus	Lower Price Target	Buy ➝ Buy	$130.00 ➝ $115.00	Low	i
11/5/2018	BMO Capital Markets	Lower Price Target	Underperform ➝ Underperform	$78.00 ➝ $71.00	Low	i
11/4/2018	Barclays	Reiterated Rating	Hold	$90.00	High	i
11/2/2018	Credit Suisse Group	Set Price Target	Hold	$85.00	High	i Rating by Vamil Divan at Credit Suisse Group AG
10/23/2018	Wolfe Research	Initiated Coverage	Underperform		Low	i
10/22/2018	SunTrust Banks	Lower Price Target	Buy ➝ Buy	$157.00 ➝ $135.00	High	i
10/20/2018	Credit Suisse Group	Set Price Target	Sell	$85.00	High	i Rating by Vamil Divan at Credit Suisse Group AG
10/14/2018	Credit Suisse Group	Set Price Target	Hold	$85.00	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
10/4/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$107.00 ➝ $106.00	Medium	i
8/22/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $107.00	Low	i Rating by Jason Gerberry at Bank of America Co.
8/22/2018	BMO Capital Markets	Reiterated Rating	Sell	$78.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
7/30/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$112.00 ➝ $105.00	Medium	i Rating by Jason Gerberry at Bank of America Co.
7/27/2018	Piper Jaffray Companies	Reiterated Rating	Hold	$100.00	Low	i
7/27/2018	Cowen	Set Price Target	Buy	$110.00	Low	i Rating by Steve Scala at Cowen Inc
7/27/2018	BMO Capital Markets	Reiterated Rating	Sell	$78.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
7/15/2018	Jefferies Financial Group	Set Price Target	Buy	$100.00	Low	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
7/13/2018	Credit Suisse Group	Upgrade	Hold	$89.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
7/12/2018	Berenberg Bank	Initiated Coverage	Hold	$105.00	Low	i
6/11/2018	Argus	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $130.00	Low	i
6/6/2018	Credit Suisse Group	Set Price Target	Sell	$89.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
6/1/2018	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$125.86 ➝ $66.62	Low	i Rating by Richard Purkiss at Piper Jaffray Companies
5/30/2018	Deutsche Bank Aktiengesellschaft	Downgrade	Neutral ➝ Underperform	$125.86 ➝ $65.61	Medium	i
5/30/2018	Deutsche Bank Aktiengesellschaft	Downgrade	Neutral ➝ Underperform	$125.86 ➝ $65.61	Low	i
5/29/2018	Credit Suisse Group	Downgrade	Neutral ➝ Sell	$104.00 ➝ $89.00	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
5/24/2018	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy		High	i
5/23/2018	BMO Capital Markets	Lower Price Target	Underperform ➝ Underperform	$81.00 ➝ $78.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
5/1/2018	BMO Capital Markets	Reiterated Rating	Sell	$81.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
4/30/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$131.00 ➝ $110.00	High	i Rating by David Risinger at Morgan Stanley
4/27/2018	Credit Suisse Group	Lower Price Target	Neutral ➝ Neutral	$109.00 ➝ $104.00	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
4/22/2018	Credit Suisse Group	Set Price Target	Hold	$109.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
4/13/2018	Jefferies Financial Group	Set Price Target	Buy	$122.00	Low	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
4/10/2018	Credit Suisse Group	Set Price Target	Hold	$109.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
4/5/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$120.00 ➝ $102.00	Low	i
4/5/2018	BMO Capital Markets	Reiterated Rating	Sell	$80.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
3/26/2018	Bank of America	Set Price Target	Hold	$120.00	High	i Rating by Jason Gerberry at Bank of America Co.
3/23/2018	Jefferies Financial Group	Set Price Target	Buy	$125.00	High	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
3/23/2018	Credit Suisse Group	Lower Price Target	Neutral	$109.00 ➝ $98.10	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
3/23/2018	BMO Capital Markets	Lower Price Target	Underperform ➝ Underperform	$95.00 ➝ $80.00	Medium	i Rating by Alex Arfaei at BMO Capital Markets
3/22/2018	BMO Capital Markets	Set Price Target	Sell	$95.00	High	i Rating by Alex Arfaei at BMO Capital Markets
3/13/2018	BMO Capital Markets	Set Price Target	Sell	$95.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
2/26/2018	Jefferies Financial Group	Set Price Target	Buy	$145.00	Low	i Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/21/2018	BMO Capital Markets	Set Price Target	Sell	$95.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
2/15/2018	BMO Capital Markets	Reiterated Rating	Sell	$95.00	High	i Rating by Alex Arfaei at BMO Capital Markets
2/15/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$130.00 ➝ $138.00	High	i Rating by Richard Purkiss at Piper Jaffray Companies
2/2/2018	Argus	Boost Price Target	Buy	$120.00 ➝ $145.00	Low	i
1/30/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$99.00 ➝ $131.00	Low	i
1/29/2018	Evercore ISI	Reiterated Rating	Buy	$144.00	Low	i
1/29/2018	Credit Suisse Group	Set Price Target	Hold	$98.00 ➝ $135.00	Medium	i Rating by Vamil Divan at Credit Suisse Group AG
1/29/2018	BMO Capital Markets	Downgrade	Market Perform ➝ Underperform	$125.86 ➝ $84.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
1/29/2018	SunTrust Banks	Boost Price Target	Buy ➝ Average	$157.00	Low	i
1/29/2018	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$127.00	Medium	i Rating by Geoff Porges at SVB Leerink LLC
1/26/2018	Piper Jaffray Companies	Boost Price Target	Outperform	$115.00 ➝ $130.00	Low	i Rating by Richard Purkiss at Piper Jaffray Companies
1/22/2018	Credit Suisse Group	Set Price Target	Hold	$98.00	Low	i Rating by Vamil Divan at Credit Suisse Group AG
1/11/2018	BMO Capital Markets	Set Price Target	Hold	$84.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
1/4/2018	Jefferies Financial Group	Boost Price Target	Buy	$115.00 ➝ $120.00	Low	i
1/2/2018	Piper Jaffray Companies	Reiterated Rating	Buy		High	i Rating by Richard Purkiss at Piper Jaffray Companies
12/20/2017	BMO Capital Markets	Set Price Target	Hold	$84.00	Medium	i Rating by Alex Arfaei at BMO Capital Markets
12/5/2017	SVB Leerink	Set Price Target	Buy	$106.00	Low	i Rating by Geoff Porges at SVB Leerink LLC
12/4/2017	BMO Capital Markets	Set Price Target	Hold	$84.00	Low	i Rating by Alex Arfaei at BMO Capital Markets
11/21/2017	BMO Capital Markets	Reiterated Rating	Hold	$84.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
11/21/2017	Societe Generale	Boost Price Target			N/A	i
10/30/2017	SunTrust Banks	Reiterated Rating	Buy		N/A	i
10/30/2017	SVB Leerink	Lower Price Target	Outperform	$108.00 ➝ $107.00	N/A	i Rating by G. Porges at SVB Leerink LLC
10/27/2017	BMO Capital Markets	Set Price Target	Hold	$66.00	N/A	i
10/27/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$115.00	N/A	i
10/16/2017	Jefferies Financial Group	Boost Price Target	Buy	$107.00 ➝ $115.00	N/A	i
10/13/2017	Barclays	Boost Price Target	Equal Weight	$90.00	N/A	i
10/13/2017	UBS Group	Reiterated Rating	Neutral		N/A	i
10/11/2017	Cowen	Upgrade	Market Perform ➝ Outperform	$91.17 ➝ $105.00	N/A	i
10/2/2017	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$89.00 ➝ $106.00	Medium	i Rating by G. Porges at SVB Leerink LLC
10/1/2017	Credit Suisse Group	Reiterated Rating	Neutral	$74.00 ➝ $94.00	Medium	i
9/30/2017	Evercore ISI	Reiterated Rating	Outperform	$95.00 ➝ $100.00	Medium	i
9/29/2017	Argus	Boost Price Target	Buy	$90.00 ➝ $110.00	Low	i
9/29/2017	Morgan Stanley	Boost Price Target	Equal Weight	$70.00 ➝ $95.00	Low	i
9/28/2017	Barclays	Reiterated Rating	Hold	$68.00	Low	i
9/28/2017	BMO Capital Markets	Reiterated Rating	Hold	$66.00	Low	i
9/28/2017	Deutsche Bank Aktiengesellschaft	Boost Price Target	Hold	$88.00	Low	i
9/28/2017	Jefferies Financial Group	Reiterated Rating	Buy	$107.00	Medium	i
9/25/2017	UBS Group	Downgrade	Buy ➝ Neutral	$79.00 ➝ $92.00	Low	i
9/15/2017	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$94.00 ➝ $107.00	High	i
9/15/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$100.00	High	i
9/13/2017	SunTrust Banks	Reiterated Rating	Buy	$95.00	Low	i
9/12/2017	SVB Leerink	Reiterated Rating	Market Perform		Low	i
9/11/2017	Cowen	Reiterated Rating	Market Perform ➝ Hold	$70.00 ➝ $95.00	Medium	i
9/8/2017	The Goldman Sachs Group	Reiterated Rating	Buy	$85.00 ➝ $100.00	Low	i
9/8/2017	Jefferies Financial Group	Reiterated Rating	Buy	$94.00	Low	i
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$95.00	Medium	i
8/3/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$85.00	Low	i
7/30/2017	Cowen	Set Price Target	Hold	$70.00	Low	i
7/20/2017	Credit Suisse Group	Reiterated Rating	Neutral	$65.00 ➝ $74.00	Medium	i
7/17/2017	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold	$65.00 ➝ $66.00	Low	i
7/17/2017	Jefferies Financial Group	Reiterated Rating	Buy	$92.00 ➝ $94.00	Low	i
6/22/2017	SVB Leerink	Reiterated Rating	Market Perform		Low	i
6/22/2017	Societe Generale	Upgrade	Hold ➝ Buy		Low	i
6/7/2017	Credit Suisse Group	Reiterated Rating	Hold	$65.00	Medium	i
5/26/2017	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
5/17/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$66.00	Low	i
5/2/2017	BMO Capital Markets	Boost Price Target	Market Perform	$63.00 ➝ $66.00	Low	i
4/28/2017	Deutsche Bank Aktiengesellschaft	Boost Price Target	Hold	$64.00 ➝ $65.00	Low	i
4/27/2017	BMO Capital Markets	Set Price Target	Hold	$63.00	Medium	i
4/20/2017	SVB Leerink	Set Price Target	Hold	$71.00	Low	i Rating by G. Porges at SVB Leerink LLC
4/18/2017	BMO Capital Markets	Reiterated Rating	Hold	$63.00	Low	i
3/22/2017	Societe Generale	Upgrade	Sell ➝ Hold		Low	i
3/22/2017	BMO Capital Markets	Reiterated Rating	Hold	$63.00	Low	i
3/11/2017	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy	$74.00 ➝ $80.00	N/A	i
3/7/2017	Jefferies Financial Group	Reiterated Rating	Top Pick ➝ Buy	$4.30 ➝ $90.00	N/A	i
2/14/2017	Jefferies Financial Group	Reiterated Rating	Buy	$90.00	N/A	i
1/5/2017	Jefferies Financial Group	Reiterated Rating	Buy	$90.00	N/A	i
12/8/2016	William Blair	Reiterated Rating	Outperform	$76.00	N/A	i
11/28/2016	Citigroup	Downgrade	Buy ➝ Neutral	$60.00	N/A	i
11/8/2016	SVB Leerink	Reiterated Rating	Hold		N/A	i Rating by G. Porges at SVB Leerink LLC
11/8/2016	BMO Capital Markets	Reiterated Rating	Market Perform	$63.00	N/A	i
11/8/2016	Citigroup	Reiterated Rating	Buy		N/A	i
11/1/2016	Jefferies Financial Group	Reiterated Rating	Buy	$90.00	N/A	i
10/31/2016	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$70.00 ➝ $60.00	N/A	i
10/18/2016	SVB Leerink	Initiated Coverage	Market Perform	$70.00	N/A	i Rating by G. Porges at SVB Leerink LLC
10/5/2016	Jefferies Financial Group	Reiterated Rating	Buy	$90.00	N/A	i
9/27/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$78.00	N/A	i
9/8/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$78.00	N/A	i
9/8/2016	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$75.00 ➝ $73.00	N/A	i
9/7/2016	UBS Group	Reiterated Rating	Buy		N/A	i
9/1/2016	Raymond James	Initiated Coverage	Outperform	$82.00	N/A	i
8/25/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
8/8/2016	Argus	Reiterated Rating	Buy	$85.00	N/A	i
8/4/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
8/2/2016	Barclays	Reiterated Rating	Equal Weight	$68.00	N/A	i
7/29/2016	BMO Capital Markets	Reiterated Rating	Market Perform	$66.00	N/A	i
7/10/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i
6/29/2016	Credit Suisse Group	Reiterated Rating	Outperform	$67.00	N/A	i
6/15/2016	UBS Group	Reiterated Rating	Buy	$73.00	N/A	i
6/10/2016	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$70.00 ➝ $66.00	N/A	i
6/8/2016	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$73.00 ➝ $65.00	N/A	i
6/7/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold		N/A	i
6/6/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
6/6/2016	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$73.00 ➝ $65.00	N/A	i
6/6/2016	UBS Group	Reiterated Rating	Buy		N/A	i
6/6/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
6/6/2016	Cowen	Downgrade	Outperform ➝ Market Perform	$77.00 ➝ $70.00	N/A	i
5/18/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Hold	$66.00	N/A	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
5/18/2016	BMO Capital Markets	Reiterated Rating	Outperform	$70.00	N/A	i Rating by Alex Arfaei at BMO Capital Markets
5/13/2016	Jefferies Financial Group	Reiterated Rating	Buy	$90.00	N/A	i Rating by Jeffrey Holford at Jefferies Financial Group Inc.
5/3/2016	BMO Capital Markets	Reiterated Rating	Buy		N/A	i Rating by Alex Arfaei at BMO Capital Markets
4/30/2016	Morgan Stanley	Reiterated Rating	Buy		N/A	i Rating by David Risinger at Morgan Stanley
4/29/2016	Jefferies Financial Group	Reiterated Rating	Buy	$90.00	N/A	i
4/26/2016	Credit Suisse Group	Reiterated Rating	Overweight		N/A	i

(Data available from 4/22/2016 forward)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Today's Range

Now: $110.05

$109.61

$111.09

50 Day Range

MA: $106.89

$103.06

$110.84

52 Week Range

Now: $110.05

$79.11

$113.41

Volume

5,043,622 shs

Average Volume

7,330,939 shs

Market Capitalization

$194.22 billion

P/E Ratio

23.27

Dividend Yield

4.69%

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of AbbVie?

The following sell-side analysts have issued research reports on AbbVie in the last year: Argus, Atlantic Securities, Bank of America Co., Berenberg Bank, BMO Capital Markets, Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist, UBS Group AG, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for ABBV.

What is the current price target for AbbVie?

16 Wall Street analysts have set twelve-month price targets for AbbVie in the last year. Their average twelve-month price target is $115.75, suggesting a possible upside of 4.5%. SVB Leerink LLC has the highest price target set, predicting ABBV will reach $144.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $95.00 for AbbVie in the next year.
View the latest price targets for ABBV.

What is the current consensus analyst rating for AbbVie?

AbbVie currently has 1 sell rating, 2 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABBV will outperform the market and that investors should add to their positions of AbbVie.
View the latest ratings for ABBV.

What other companies compete with AbbVie?

Other companies that are similar to AbbVie include Johnson & Johnson, Pfizer, Merck & Co., Inc., Eli Lilly and, Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics, Supernus Pharmaceuticals and Endo International.

How do I contact AbbVie's investor relations team?

AbbVie's physical mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company's listed phone number is 847-932-7900. The official website for AbbVie is www.abbvie.com.

NYSE:ABBV - AbbVie Stock Price Target and Predictions

Analyst Price Target for ABBV

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of AbbVie?

What is the current price target for AbbVie?

What is the current consensus analyst rating for AbbVie?

What other companies compete with AbbVie?

How do I contact AbbVie's investor relations team?